Android app Apple app link

AAN 2025: J&J reveals data for nipocalimab, showing long-term disease control in MG

By Yahoo! Finance   |   1 month ago
AAN 2025: J&J reveals data for nipocalimab, showing long-term disease control in MG

Johnson & Johnson presented positive results from the Vivacity-MG3 study on nipocalimab for treating myasthenia gravis.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.